20:44 , Jul 25, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Pancreatic cancer Cell culture and mouse studies suggest inhibiting PARP in combination with ELAVL1 could help treat pancreatic ductal adenocarcinoma (PDAC). In two human PDAC cell lines treated with the PARP inhibitors Lynparza olaparib or...
07:00 , Jun 2, 2016 |  BC Innovations  |  Product R&D

Local reagent makes good

Genisphere LLC is converting its 19 year-old diagnostic reagents into new-age delivery vehicles. The company is repurposing its 3DNA assay technology into nanoparticles that it believes can bring high-valency cargo to target tissues without getting...
07:00 , Mar 31, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Elav like RNA binding protein 1 (ELAVL1)

Cancer INDICATION: Ovarian cancer Patient sample and mouse studies suggest inhibiting ELAVL1 could help treat ovarian cancer. ELAVL1 levels were higher in primary tumors from ovarian cancer patients than in ovarian tissue from healthy controls. In a...